Unlocking global access to Bacillus Calmette-Guerin (BCG) for cancer therapy. ImmunityBio partners with Serum Institute to ...

ImmunityBio last week won the FDA’s approval for its immunotherapy Anktiva to be used alongside the Bacillus Calmette-Guérin (BCG) vaccine to treat certain patients with bladder cancer. Problem is, ...

ImmunityBio has yet to finalize a registrational trial plan with the FDA in that papillary disease population, Soon-Shiong ...

iBCG is intended for use along with ImmunityBio’s ANKTIVA (nogapendekin alfa inbakicept-pmln) for approved and additional ...

ImmunityBio has financial resources for the short-term, but long-term financial health remains uncertain. Click here to read ...

The Food and Drug Administration on Monday approved Culver City-based ImmunityBio’s treatment for bladder cancer.

ImmunityBio (NASDAQ: IBRX) stock price has gone parabolic as investors cheer the recent approval of Anktiva, its cancer drug.

ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) ...

After years of effort, delays and hundreds of millions of dollars of billionaire Patrick Soon-Shiong’s own money, last week ...

ImmunityBio finally received FDA approval for its drug ANKTIVA for the treatment of patients with BCG-unresponsive NMIBC with ...

ImmunityBio (NASDAQ: IBRX) stock price resumed its strong rally this week after the company achieved a major milestone. After ...

Collaboration will result in BCG manufacture at large scale for use in combination with ANKTIVA®, ImmunityBio’s recently ...